drugset / Trial / NCT06008275
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
NaSingle-groupOpen-labelHealth-services research
Summary
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Timeline
- Start
- 2024-09-16
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |